Semaglutide offers weight-loss-independent benefits in MASH

New research offers surprising insights into the benefits of glucagon-like peptide 1 (GLP-1) drugs for patients with metabolic dysfunction-associated steatohepatitis (MASH).

A report published in the journal Cell Metabolism suggests GLP-1 drugs, such as Wegovy (semaglutide), improve liver health regardless of their impact on a patient’s weight.

The idea that patients with MASH might benefit from GLP-1 therapies is not in itself a new idea. Weight loss is one of the primary strategies clinicians use to help patients with MASH, and Wegovy has led to dramatic weight loss for many patients with obesity or who are overweight. The FDA added MASH as an indication to Wegovy’s approvals in August 2025. There’s evidence, some of it quite early and in need of confirmation, that the GLP-1s can help patients with a wide array of conditions, including atherosclerosis, diabetic kidney disease, obstructive sleep apnea and even knee osteoarthritis.

The new report suggests the effect of semaglutide on patients with MASH isn’t just mediated through weight loss.

“We’ve seen in clinical trials that patients who lose very little weight see the same reductions in liver inflammation, scarring, and enzyme levels as those who lose a great deal of weight,” the study’s lead author, Daniel Drucker, M.D, said in a press release. “Now we know why.”

Drucker is a senior investigator at the Lunenfeld-Tanenbaum Research Institute, part of Toronto’s Sinai Health. He and his colleagues have been working on GLP-1 research since the 1980s, and their findings have helped lead to the current revolution in diabetes and obesity care.

The addition of MASH as an indication for Wegovy was based on the strength of results from a phase 3 trial. According to a planned 72-week interim analysis, slightly more than 6 in 10 (63%) of patients with MASH who took Wegovy in addition to lifestyle changes experienced MASH resolution and no worsening of liver scarring, compared with 34% of patients receiving placebo and making lifestyle changes. Thirty-seven percent of patients in the Wegovy cohort had improvement in liver scarring without worsening of MASH, versus 22% in the placebo cohort. That trial is ongoing and was expected to continue for a total of 240 weeks (approximately four and a half year)

In Drucker’s new report, the investigators studied semaglutidein a mouse model of MASH. They found that even mice who were resistant to GLP-1-induced weight loss benefited from Wegovy. This finding led Drucker and his colleague, postdoctoral fellow Maria Gonzalez-Rellan, Ph.D., to conduct a deep molecular analysis of liver cells. They found two types of cells in the liver carry semaglutide receptors: liver sinusoidal endothelial cells (LSECs) and immune T cells.

LSECs make up only about 3% of liver cells, but they play a crucial role by lining blood vessels in the liver and acting as a molecular filter between the liver and the bloodstream, the investigators explained. They found that semaglutide shifts the gene activity of LSECs so that the cells release anti-inflammatory molecules that in turn lead to a healthier liver.

“It turns out that the receptor responsible for these benefits [of semaglutide] is in a very specialized population of liver cells,” Drucker said. “And this receptor orchestrates the production of molecules that talk to many different types of liver cells to calm down the inflammatory environment that is the problem in metabolic disease.”

Drucker and Gonzalez-Rellan also tested semaglutide in mice with MASH that lacked LSEC receptors. Those mice lost body weight but the health of their livers did not improve. Drucker and his colleagues said that and other findings point to LSECs activity as the key mechanism by which semaglutide benefits these patients.

The investigators said their findings could be useful to clinicians treating patients with MASH. For instance, they said it might be possible for physicians to use lower doses of semaglutide when treating patients for MASH, which could in turn lower the risk of side effects and potentially lower the cost of therapy. Drucker added that the findings also demonstrate that weight loss should not be viewed as the only possible measure of treatment success in these patients.